(Q45137439)

English

Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study

scientific article published on 3 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1 reference

based on heuristic

inferred from title

author name string

Tomoyuki Shimabukuro

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Shigeru Sakano

2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Kenji Matsuda

3

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Yoriaki Kamiryo

4

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Norio Yamamoto

5

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Yoshitaka Kaneda

6

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Takahito Nasu

7

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Yoshikazu Baba

8

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Akinobu Suga

9

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Mitsutaka Yamamoto

10

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Akihiko Aoki

11

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Kimio Takai

12

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Satoru Yoshihiro

13

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Motohiko Konishi

14

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Katsuhiko Imoto

15

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Hideyasu Matsuyama

16

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

publication date

3 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

International Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

62-67

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

https://scigraph.springernature.com/pub.10.1007/s10147-011-0344-x

0 references

Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

Mechanisms of androgen-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0344-X

21 January 2018

Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results

1 reference

https://pubmed.ncbi.nlm.nih.gov/22068464

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association

1 reference

https://pubmed.ncbi.nlm.nih.gov/22068464

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/22068464

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10147-011-0344-X

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45137439&oldid=2066756789"